Insmed Shares Fall on Termination of Drug Development Program

Dow Jones12-18 23:48

By Elias Schisgall

Shares of Insmed were lower after the pharmaceutical company said it was discontinuing development of its brensocatib treatment for patients with chronic rhinosinusitis without nasal polyps.

Shares dropped 16% to $167.39 in Thursday morning trading. The stock has risen by nearly two-and-a-half times its value this year.

Insmed terminated the development program Wednesday after a Phase 2b study of the treatment for chronic rhinosinusitis failed to meet its primary or secondary endpoints.

The company also said Wednesday that it had acquired an antibody treatment from Opsidio. Insmed said it is looking to launch Phase 2 studies of the treatment for interstitial lung disease and moderate-to-severe asthma.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

December 18, 2025 10:48 ET (15:48 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592486900?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 23:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592486900","market":"us","top_or_hot":-1,"title":"Insmed Shares Fall on Termination of Drug Development Program","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INSM\">Insmed</a> were lower after the pharmaceutical company said it was discontinuing development of its brensocatib treatment for patients with chronic rhinosinusitis without nasal polyps. \n</p>\n<p>\n  Shares dropped 16% to $167.39 in Thursday morning trading. The stock has risen by nearly two-and-a-half times its value this year. \n</p>\n<p>\n  Insmed terminated the development program Wednesday after a Phase 2b study of the treatment for chronic rhinosinusitis failed to meet its primary or secondary endpoints. \n</p>\n<p>\n  The company also said Wednesday that it had acquired an antibody treatment from Opsidio. Insmed said it is looking to launch Phase 2 studies of the treatment for interstitial lung disease and moderate-to-severe asthma. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2025 10:48 ET (15:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed Shares Fall on Termination of Drug Development Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed Shares Fall on Termination of Drug Development Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-18 23:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INSM\">Insmed</a> were lower after the pharmaceutical company said it was discontinuing development of its brensocatib treatment for patients with chronic rhinosinusitis without nasal polyps. \n</p>\n<p>\n  Shares dropped 16% to $167.39 in Thursday morning trading. The stock has risen by nearly two-and-a-half times its value this year. \n</p>\n<p>\n  Insmed terminated the development program Wednesday after a Phase 2b study of the treatment for chronic rhinosinusitis failed to meet its primary or secondary endpoints. \n</p>\n<p>\n  The company also said Wednesday that it had acquired an antibody treatment from Opsidio. Insmed said it is looking to launch Phase 2 studies of the treatment for interstitial lung disease and moderate-to-severe asthma. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2025 10:48 ET (15:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592486900","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592486900","pubTimestamp":1766072880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Insmed were lower after the pharmaceutical company said it was discontinuing development of its brensocatib treatment for patients with chronic rhinosinusitis without nasal polyps.Shares dropped 16% to $167.39 in Thursday morning trading. The stock has risen by nearly two-and-a-half times its value this year.Insmed terminated the development program Wednesday after a Phase 2b study of the treatment for chronic rhinosinusitis failed to meet its primary or secondary endpoints.The company also said Wednesday that it had acquired an antibody treatment from Opsidio. Insmed said it is looking to launch Phase 2 studies of the treatment for interstitial lung disease and moderate-to-severe asthma.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","INSM":"Insmed","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Insmed股价因药物开发计划终止而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Insmed were lower after the pharmaceutical company said it was discontinuing development of its brensocatib treatment for patients with chronic rhinosinusitis without nasal polyps. \n\n\n  Shares dropped 16% to $167.39 in Thursday morning trading. The stock has risen by nearly two-and-a-half times its value this year. \n\n\n  Insmed terminated the development program Wednesday after a Phase 2b study of the treatment for chronic rhinosinusitis failed to meet its primary or secondary endpoints. \n\n\n  The company also said Wednesday that it had acquired an antibody treatment from Opsidio. Insmed said it is looking to launch Phase 2 studies of the treatment for interstitial lung disease and moderate-to-severe asthma. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 10:48 ET (15:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592486900","isCrawlerRequest":true}